ABO and female reproductive organ cancer: We therefore retrospectively evaluated and compared the clinic-pathological findings including relapse-free survival (RFS), disease-specific survival (DSS), and overall survival (OS) of a large gynecological cancer patient cohort (n = 974) to the ABO BG status.